BridgeMD
New treatment option for Glioblastoma, IDH-Wildtype
Official title Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
ClinicalTrials.gov ID: NCT07091864
What this study is testing
- What it's testing
- This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Presumed newly diagnosed GBM based on imaging findings consistent with GBM on brain MRI (e.g., heterogeneously enhancing mass with central necrosis...
- Age ≥ 18 years at the time of consent
- Karnofsky performance status (KPS) ≥ 70 at baseline
- Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L
- Platelet count ≥ 100 × 10\^9/L
You likely can't join if
- Recurrent glioblastoma or prior therapy for glioblastoma beyond surgical resection or biopsy
- History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months
- Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the...
- Concurrent diagnosis of another active malignancy requiring treatment
- Pregnancy or breastfeeding at the time of enrollment
- Documented history of type 1 diabetes mellitus
See the full eligibility criteria
- Presumed newly diagnosed GBM based on imaging findings consistent with GBM on brain MRI (e.g., heterogeneously enhancing mass with central necrosis and surrounding edema), as determined by the treating neuro-oncology...
- Age ≥ 18 years at the time of consent
- Karnofsky performance status (KPS) ≥ 70 at baseline
- Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L
- Platelet count ≥ 100 × 10\^9/L
- Hemoglobin ≥ 9 g/dL
- Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN
- Total bilirubin ≤ 1.5 × ULN
- Willingness and ability to comply with CGM device use and attend dietary counseling sessions as part of the study protocol
- Recurrent glioblastoma or prior therapy for glioblastoma beyond surgical resection or biopsy
- History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months
- Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the opinion of the investigator, would interfere with study participation...
- Concurrent diagnosis of another active malignancy requiring treatment
- Pregnancy or breastfeeding at the time of enrollment
- Documented history of type 1 diabetes mellitus
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
- Jacksonville, Florida, United States
- Rochester, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States; Jacksonville, Florida, United States; Rochester, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.